- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02268435
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Fase
- Fase 1
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 19 years or older
- Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
- Disease control (response or stabilization for at least 6 months with first-line imatinib and failure of prior treatments for GIST, including at least both imatinib and sunitinib and/or regorafenib. However, patients with imatinib rechallenge will not be accrued.
- ECOG performance status of 0~2
- Resolution of all toxic effects of prior treatments to grade 0 or 1
- At least one evaluable or measurable lesion for phase I study
Adequate bone marrow, hepatic, renal, and other organ functions
- Neutrophil > 1,500/mm3
- Platelet > 75,000/mm3
- Hemoglobin > 8.0 g/dL
- Total bilirubin < 1.5 x upper limit of normal
- AST/ALT < 2.5 x ULN with no exceptions
- Creatinine < 1.5 x ULN
- Life expectancy > 12 weeks
- Women with reproductive potential must have a negative serum or urine pregnancy test; and men and women of reproductive potential must practice an effective method of avoiding pregnancy while receiving study drug.
- Washout period of previous TKIs or chemotherapy for more than 4 times the half life.
- No prior use of dovitinib or other inhibitors of FGFR except regorafenib
- Provision of a signed written informed consent
Exclusion Criteria:
- Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes.
Clinically significant cardiac disease or impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- LVEF < 45%
- Complete left bundle branch block
- Obligate use of a cardiac pacemaker
- Congenital long QT syndrome
- History or presence of ventricular tachyarrhythmia
- Presence of unstable atrial fibrillation .
- Clinically significant resting bradycardia
- Uncontrolled hypertension
- QTc > 480 msec on screening ECG
- Right bundle branch block + left anterior hemiblock
- Angina pectoris ≤ 3 months prior to starting study drug
- Acute Myocardial Infarction ≤ 3 months prior to starting study drug
- Other clinically significant heart disease
- Uncontrolled infection
- Subjects who did not tolerate previous imatinib treatment.
- Diabetes mellitus with signs of clinically significant peripheral vascular disease
- Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month 7. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands
8. Prior acute or chronic pancreatitis of any etiology 9. Malabsorption syndrome or uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2 10. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study 11. Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug 12. Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior baseline 13. Major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy 14. Known diagnosis of HIV infection 15. History of another primary malignancy that is currently clinically significant or currently requires active intervention 16. Patients with brain metastases as assessed by radiologic imaging due to symptoms clinically suspected of brain metastases 17. Alcohol or substance abuse disorder
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Dovitinib plus Imatinib
Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
|
Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Maximal tolerated dose and recommended dose
Lasso di tempo: 3 years
|
Initially three patients will be treated at each dose level.
If one out of three patients experiences a DLT, three additional patients will be entered at that dose level.
Dose escalation will be continued until DLTs are experienced in two or more out of six patients (more than 33% of patient cohort), which will be defined as the MTD.If more than 33% of patients experience a DLT in a dose level, one doe level below will be the RD
|
3 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Disease control rate
Lasso di tempo: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Overall response rate
Lasso di tempo: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Number of Participants with Adverse Events as a Measure of Safety
Lasso di tempo: 3 years
|
Safety by NCI CTCAE version 4.0
|
3 years
|
Progression-free survival
Lasso di tempo: 3 years
|
response + stable disease evaluated with abdominal and pelvic spiral CT scan every 4 weeks for the first 8 weeks, and then every 8 weeks, using RECIST criteria v1.1
|
3 years
|
Overall survival (OS)
Lasso di tempo: 3 years
|
OS assessment dates will be the time point when 6 months have passed after the enrollment of the last patient
|
3 years
|
optionally, correlation of efficacy with potential biomarkers
Lasso di tempo: 3 years
|
mutational analysis of KIT exons 9, 11, 13, and 17, and PDGFRα exons 12, 14, and 18 with direct sequencing using DNA extracted from archival tissues and/or newly obtained tissues at baseline, and with BEAMing assay using ctDNA extracted from plasma at baseline and every time when follow-up CT scans are conducted; optionally circulating growth factors including but not limited to VEGF, bFGF, IL-8, PLGF, FGFR2, and FGF23, and soluble receptors including but not limited to sVEGFR1 and 2 with plasma collected at baseline and on Cycle 1 Week 4 Day 5
|
3 years
|
next generation sequencing will be performed in newly obtained tissues at baseline to find out new genetic changes after failure of previous standard TKIs
Lasso di tempo: 3 years
|
3 years
|
|
Optionally, activation of FGFR signaling will be analyzed using the reverse phase protein microarray and/or immunohistochemistry including but not limited to pFRS2 and pFGFR in archival tissues and/or newly obtained tissues at baseline
Lasso di tempo: 3 years
|
3 years
|
|
Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters
Lasso di tempo: 3 years
|
PK samples will be taken at 0 hour (pre-dose) and at 1, 2, 3, 4, 6, and 8 hours (post-dose) after administration of dovitinib and imatinib on Cycle 1 Week 1 Day 1, Cycle 1 Week 1 Day 5, and Cycle 1 Week 4 Day 5
|
3 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Yoon-Koo Kang, PhD, Asan Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Neoplasie, Connettivo e Tessuto Molle
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie, tessuto connettivo
- Tumori stromali gastrointestinali
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori della chinasi proteica
- Imatinib mesilato
Altri numeri di identificazione dello studio
- AMC1401
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su dovitinib plus imatinib
-
Novartis PharmaceuticalsCompletatoNeoplasie | Cancro | TumoriStati Uniti
-
Abramson Cancer Center of the University of PennsylvaniaCompletatoParaganglioma non resecabile | Feocromocitoma ricorrente | Paraganglioma Metastatico Avanzato | Feocromocitoma metastatico avanzato | Paraganglioma ricorrente | Feocromocitoma non resecabileStati Uniti
-
Samsung Medical CenterSconosciutoNSCLC squamosoCorea, Repubblica di
-
Yonsei UniversityCompletatoCancro alla tiroideCorea, Repubblica di
-
Novartis PharmaceuticalsCompletatoCancro al seno metastaticoStati Uniti, Canada, Finlandia, Francia, Italia, Spagna, Taiwan, Regno Unito
-
M.D. Anderson Cancer CenterNovartisTerminato
-
Korean Cancer Study GroupCompletatoCancro alla prostata refrattario agli ormoniCorea, Repubblica di
-
Novartis PharmaceuticalsCompletatoAttivazioni della via tumorale inibite da DovitinibStati Uniti
-
Novartis PharmaceuticalsCompletatoTumore endometriale | VEGF | Tumori solidi e carcinoma endometriale avanzato | Trattamento di seconda lineaItalia, Regno Unito, Spagna, Brasile, Stati Uniti, Corea, Repubblica di, Nuova Zelanda
-
Auckland District Health BoardNovartis; University of Auckland, New Zealand; IGENZ, Ltd., AucklandSconosciutoCarcinoma a cellule renali a cellule chiareNuova Zelanda